281 related articles for article (PubMed ID: 28453697)
21. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.
Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF
Cancer; 2020 Sep; 126(18):4136-4147. PubMed ID: 32697360
[TBL] [Abstract][Full Text] [Related]
22. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
[TBL] [Abstract][Full Text] [Related]
23. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
24. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
[TBL] [Abstract][Full Text] [Related]
25. Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.
Sperlich A; Balmert A; Doll D; Bauer S; Franke F; Keller G; Wilhelm D; Mur A; Respondek M; Friess H; Nitsche U; Janssen KP
BMC Cancer; 2018 Oct; 18(1):998. PubMed ID: 30340556
[TBL] [Abstract][Full Text] [Related]
26. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
27. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
29. A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer.
Zhou R; Zeng D; Zhang J; Sun H; Wu J; Li N; Liang L; Shi M; Bin J; Liao Y; Huang N; Liao W
EBioMedicine; 2019 Apr; 42():420-430. PubMed ID: 30917936
[TBL] [Abstract][Full Text] [Related]
30. High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer.
Zaanan A; Calmel C; Henriques J; Svrcek M; Blons H; Desbois-Mouthon C; Merabtene F; Goumard C; Parc Y; Gayet B; Taieb J; Validire P; Louvet C; Fléjou JF; Le Bouc Y; Praz F
Cell Oncol (Dordr); 2020 Apr; 43(2):237-247. PubMed ID: 31823290
[TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of Src activation in stage II-III colon cancer.
Martínez-Pérez J; Lopez-Calderero I; Saez C; Benavent M; Limon ML; Gonzalez-Exposito R; Soldevilla B; Riesco-Martínez MC; Salamanca J; Carnero A; Garcia-Carbonero R
Hum Pathol; 2017 Sep; 67():119-125. PubMed ID: 28601656
[TBL] [Abstract][Full Text] [Related]
32. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
33. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
34. pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited.
Snaebjornsson P; Coupe VM; Jonasson L; Meijer GA; van Grieken NC; Jonasson JG
Int J Cancer; 2014 Jul; 135(2):467-78. PubMed ID: 24347179
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
[TBL] [Abstract][Full Text] [Related]
36. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients.
Greene FL; Stewart AK; Norton HJ
Ann Surg; 2002 Oct; 236(4):416-21; discussion 421. PubMed ID: 12368669
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
[TBL] [Abstract][Full Text] [Related]
38. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.
de Vos tot Nederveen Cappel WH; Meulenbeld HJ; Kleibeuker JH; Nagengast FM; Menko FH; Griffioen G; Cats A; Morreau H; Gelderblom H; Vasen HF
Int J Cancer; 2004 Apr; 109(3):468-71. PubMed ID: 14961589
[TBL] [Abstract][Full Text] [Related]
39. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M
BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182
[TBL] [Abstract][Full Text] [Related]
40. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]